↓ Skip to main content

Dietary Supplement Use and Prostate Cancer Risk in the Carotene and Retinol Efficacy Trial

Overview of attention for article published in Cancer Epidemiology, Biomarkers & Prevention, August 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
9 X users
patent
1 patent

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
70 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dietary Supplement Use and Prostate Cancer Risk in the Carotene and Retinol Efficacy Trial
Published in
Cancer Epidemiology, Biomarkers & Prevention, August 2009
DOI 10.1158/1055-9965.epi-09-0013
Pubmed ID
Authors

Marian L. Neuhouser, Matt J. Barnett, Alan R. Kristal, Christine B. Ambrosone, Irena B. King, Mark Thornquist, Gary G. Goodman

Abstract

We investigated dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial (CARET). CARET was a randomized, double-blinded, placebo-controlled trial testing a daily dose of 30 mg beta-carotene + 25,000 IU retinyl palmitate for lung cancer prevention (1985-1996; active follow-up occurred through 2005). Secondary outcomes, including prostate cancer, were also assessed. Participants were queried about dietary supplements, health history, family history of cancer, smoking, and lifestyle habits. Cox proportional hazards regression estimated multivariate-adjusted relative risk [and 95% confidence intervals (95% CI)] of prostate cancer for dietary supplement users and nonusers with or without the high-dose CARET vitamins during the intervention and postintervention phases. After an average of 11 years of follow-up, 890 prostate cancer cases were reported. Neither the CARET nor other supplements were associated with total prostate cancer risk. For aggressive prostate cancer, men in the CARET intervention arm who used additional supplements had a relative risk for aggressive prostate cancer (Gleason >or=7 or stage III/IV) of 1.52 (95% CI, 1.03-2.24; P < 0.05), relative to all others. These associations disappeared in the postintervention period (0.75; 95% CI, 0.51-1.09). Conversely, there was no association of CARET + other supplements with nonaggressive disease, relative to all others. There was no effect modification by smoking or time on CARET intervention in any analyses. CARET only included smokers, so findings reported here may not apply to nonsmokers. Our results are consistent with other studies suggesting that dietary supplements may influence prostate cancer risk.

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
United States 1 1%
Unknown 68 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 14%
Researcher 10 14%
Student > Master 8 11%
Student > Bachelor 7 10%
Other 4 6%
Other 9 13%
Unknown 22 31%
Readers by discipline Count As %
Medicine and Dentistry 19 27%
Agricultural and Biological Sciences 8 11%
Biochemistry, Genetics and Molecular Biology 6 9%
Engineering 3 4%
Materials Science 2 3%
Other 10 14%
Unknown 22 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2015.
All research outputs
#4,093,922
of 25,374,917 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#1,160
of 4,848 outputs
Outputs of similar age
#17,759
of 123,265 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#5
of 39 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,848 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.4. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 123,265 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.